Nautilus Biotechnology (NAUT) Q3 2026 Earnings Call: Voyager Launch Roadmap and Cash Runway
Source Tradingkey
Key Takeaways
- Nautilus Biotechnology reported Q3 2026 revenue of $0.2 million from Early Access services and grant funding, reflecting its early commercial stage ahead of the Voyager platform launch.
- Net loss widened to $15.6 million, or $0.12 per share, from $13.6 million, or $0.11 per share, a year earlier. Operating expenses increased 10% to $16.9 million.
- Cash, cash equivalents and investments ended the quarter at $114.3 million. Management expects the current financial plan to provide a cash runway into Q1 2028.
- The company now expects total 2026 revenue to exceed its previous outlook of approximately $0.5 million. Q4 revenue is expected to grow sequentially even without contributions from the ARPA-H-funded SEEDS program.
- Nautilus plans to open Voyager platform preorders in early 2027 and begin instrument shipments in mid-2027. Tau, AKT1 and a second oncology assay are expected to be generally available alongside shipments.
- The company remains focused on developing 20 proteoform assays by mid-2028. It may raise additional capital between now and mid-2027 to expand its assay portfolio, platform capabilities and commercial team.
Core Financial Data
| Metric | Q3 2026 | Comparison / Commentary |
|---|---|---|
| Revenue | $0.2 million | Early Access service revenue and Michael J. Fox Foundation grant revenue |
| Operating expenses | $16.9 million | Up approximately 10% from $15.5 million in Q3 2025 |
| R&D expenses | $10.2 million | Up approximately 6% from $9.6 million, mainly due to personnel, laboratory and professional services costs |
| SG&A expenses | $6.8 million | Up approximately 15% from $5.9 million, driven by legal, marketing and personnel costs |
| Net loss | $15.6 million | Compared with $13.6 million in Q3 2025 |
| Net loss per share | $0.12 | Compared with $0.11 in Q3 2025 |
| Cash, cash equivalents and investments | $114.3 million | Down from $129.2 million at the end of Q2 2026 |
| Quarterly cash use | Approximately $14.9 million | Reflected investments in assay development and launch preparation |
Business and Operating Performance
Disclaimer: For information purposes only. Past performance is not indicative of future results.
Recommended Articles
Fed October Rate Decision Preview: Rate Hike Pause Has Become Consensus, How Will US Stocks, Dollar, and Gold React?The Federal Reserve will announce its October interest rate decision at 14:00 Eastern Time on October 28, and Fed Chair Warsh will hold a press conference at 14:30. Markets currently wide
The Federal Reserve will announce its October interest rate decision at 14:00 Eastern Time on October 28, and Fed Chair Warsh will hold a press conference at 14:30. Markets currently wide
Anthropic files for a $2 trillion IPO — the $80.7 billion loss is the decoy, the $450 billion compute bill is the riskAnthropic publicly filed its S-1 on October 26, revealing $16.29 billion of first-half revenue (+1,304% year over year) and a $80.7 billion net loss — of which $72.4 billion is a non-cash convertible-note charge. The real number is the $450 billion of signed, mostly non-cancelable compute commitments. Here is what the filing says, why NVDA, ARM and MU are the tradeable read-through, and the conditions that decide whether the AI trade passes its first public valuation test.
Anthropic publicly filed its S-1 on October 26, revealing $16.29 billion of first-half revenue (+1,304% year over year) and a $80.7 billion net loss — of which $72.4 billion is a non-cash convertible-note charge. The real number is the $450 billion of signed, mostly non-cancelable compute commitments. Here is what the filing says, why NVDA, ARM and MU are the tradeable read-through, and the conditions that decide whether the AI trade passes its first public valuation test.
Tesla jumps 5% as Barclays puts a $450 target on the SpaceX merger — the chart was already pointing to 431Tesla closed at $391.62 on October 26, up 5.21%, after Barclays upgraded the stock to Overweight and lifted its target to $450 from $370, citing a sharp inflection in Robotaxi miles and a potential SpaceX merger. The move also completed a double bottom at $345.88 and $349.33, with a neckline at $388.56 and a measured target of $431.24. Here is what the upgrade actually says, why the chart and the analyst now point the same way, and what would break the target.
Tesla closed at $391.62 on October 26, up 5.21%, after Barclays upgraded the stock to Overweight and lifted its target to $450 from $370, citing a sharp inflection in Robotaxi miles and a potential SpaceX merger. The move also completed a double bottom at $345.88 and $349.33, with a neckline at $388.56 and a measured target of $431.24. Here is what the upgrade actually says, why the chart and the analyst now point the same way, and what would break the target.
Euro weakens below 1.1200 as traders brace for Fed, ECB rate decisionsThe EUR/USD pair extends the decline near 1.1170 during the early Asian trading hours on Tuesday, pressured by risk-off sentiment. Markets might turn cautious later in the day ahead of the US Federal Reserve (Fed) and European Central Bank (ECB) interest rate decisions later this week.
The EUR/USD pair extends the decline near 1.1170 during the early Asian trading hours on Tuesday, pressured by risk-off sentiment. Markets might turn cautious later in the day ahead of the US Federal Reserve (Fed) and European Central Bank (ECB) interest rate decisions later this week.
Bitcoin falls below the $80,000 mark as the October FOMC decision approaches, threatening a further dip toward $75,000.On October 26, Bitcoin (BTC) again lost the key psychological mark o
